This is a research study for men and women who are 18 years of age or older with ongoing chronic hepatitis (HCV) and are enrolled in a drug treatment program.
   
The purpose of this research study is to test and treat strategy with simplified video-based patient education versus standard of care referral with Health Care Provider (HCP) delivered patient education. This research study will also assess point of care Cepheid Viremia (RNA) test as compared to standardized laboratory HCV assessments.
   
This research study will use drug called glecaprevir/pibrentasvir (G/P). It contains two drugs for treating HCV in one pill. G/P belongs to a group of drugs called direct-acting antiviral agents (DAAs). G/P prevent HCV from multiplying and spreading in the human body. 
 
G/P is approved by the United States of America Food and Drug Administration (USA FDA) for the treatment of chronic hepatitis without or with cirrhosis (scarring of the liver).

Participation in this study will last approximately 24 weeks.